Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifamycin SV MMX in Minimal Hepatic Encephalopathy
NCT04082780Phase 2Completed
- Sponsor
- Richmond VA Medical Center
- Start
- Sep 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic encephalopathy (HE) comparing Rifamycin SV MMX with Placebo (2 arms). Primary endpoint: Cirrhosis Dysbiosis Ratio of stool microbiota at 30 days. Started Sep 2019; status: completed.
02
Drugs
rifamycin SV-MMX
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04082780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082780.